|
- argenx | Homepage - Reaching Patients Through Immunology Innovation
At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies
- argenx | Pipeline
argenx engineers first-in-class therapies for rare diseases – where underserved patients need breakthroughs and the healthcare community needs options Our franchise-focused approach to development has created a pipeline that is as broad as it is deep, allowing us to advance select opportunities ourselves while partnering others
- argenx | Pipeline - Differentiated Immunology Solutions
argenx engineers first-in-class therapies for rare diseases – where underserved patients need breakthroughs and the healthcare community needs options Our franchise-focused approach to development has created a pipeline that is as broad as it is deep, allowing us to advance select opportunities ourselves while partnering others
- argenx | About - One Team, One Culture, One Purpose
The name argenx comes from the ancient myth of the Argonauts – one of the first stories on record recognizing the power of the team rather than one hero The Argonauts set out in a small boat on a wide ocean on a mission to find the golden fleece
- Company Profile - argenx Annual Report 2024
As a result, since January 1, 2017, (i) argenx BV holds all legal and economic ownership of our intellectual property rights, and (ii) the research and development agreement between argenx SE and argenx BV has been terminated
- argenx Careers
At argenx, we are redefining how a biotech company can advance science and deliver innovative treatments We're enabling new ways of working with partners, patients and each other
- Clinical Trials - Argenx
At argenx, we are united in our commitment to improve the lives of patients by translating immunology innovations into transformative medicines The path to pioneer innovations and advance the understanding of autoimmune disease is best achieved through co-creation with patients and their supporters, and our patient advocacy partners
- Annual Report 2024 | argenx – Home
Read the entire argenx Annual Report 2024 online – the financial year, corporate governance, patient stories and much more
|
|
|